Free Trial
NASDAQ:FBRX

Forte Biosciences Q1 2025 Earnings Report

Forte Biosciences logo
$11.32 +0.97 (+9.37%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$11.27 -0.05 (-0.44%)
As of 06/6/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences EPS Results

Actual EPS
-$1.37
Consensus EPS
-$0.89
Beat/Miss
Missed by -$0.48
One Year Ago EPS
N/A

Forte Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Forte Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Forte Biosciences' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Forte Biosciences Earnings Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
TD Cowen Remains a Buy on Forte Biosciences (FBRX)
Forte Biosciences price target lowered to $61 from $64 at Chardan
See More Forte Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Forte Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Forte Biosciences and other key companies, straight to your email.

About Forte Biosciences

Forte Biosciences (NASDAQ:FBRX) operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

View Forte Biosciences Profile

More Earnings Resources from MarketBeat